비욘드바이오

Colorectal cancer

Colorectal cancer is the third most commonly diagnosed cancer in the world due to genetic factors, westernized lifestyles, and an aging population. The overall 5-year survival rate is high at 65%, but despite the development of new treatments, the 5-year survival rate for metastatic colorectal cancer is very low at less than 20%, ranking it third in mortality among all cancers.

Early-stage colorectal cancer is often asymptomatic, and symptoms usually appear as the cancer progresses. Therefore, stage IV colorectal cancer accounts for about 20% of all diagnoses, and if it has metastasized to the liver or lungs, the median overall survival is less than 30 months, making it a cancer with a poor prognosis.

Colorectal cancer treatment can include surgery, chemotherapy but approximately 60-70% of patients with metastatic colorectal cancer cannot be resected despite chemotherapy, and the recurrence rate is high due to chemo-resistance.

BeyondBio’s anticancer drug is expected to exhibit high therapeutic effects by regulating drug resistance by inhibiting the growth and recurrence of cancer through the elimination of cancer stem cells that cause cancer development and metastasis. As a good combination treatment with Capecitabine, a first-line treatment, it will increase the survival rate of cancer patients and contribute to improving their quality of life.

In addition, as a combination therapy with an immune checkpoint inhibitor, BeyondBio’s anticancer drug is expected to boost the immunogenicity of cancer, induce a more robust antitumor immunity, and inhibit cancer growth, thereby improving the prognosis of colorectal cancer patients, and provide hope to patients with metastatic colorectal cancer to overcome the disease.